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Abstract
Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular dis-
order leading to paralysis and subsequent death in young children. Initially
considered a motor neuron disease, extra-neuronal involvement is increasingly
recognized. The primary goal of this study was to investigate alterations in lipid
metabolism in SMA patients and mouse models of the disease. Methods: We
analyzed clinical data collected from a large cohort of pediatric SMA type I–III
patients as well as SMA type I liver necropsy data. In parallel, we performed
histology, lipid analysis, and transcript profiling in mouse models of SMA.
Results: We identify an increased susceptibility to developing dyslipidemia in a
cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly,
fatty acid metabolic abnormalities were present in all SMA mouse models stud-
ied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dys-
lipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly,
this phenotype appeared prior to denervation. Interpretation: This work high-
lights metabolic abnormalities as an important feature of SMA, suggesting
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implementation of nutritional and screening guidelines in patients, as such
defects are likely to increase metabolic distress and cardiovascular risk. This
study emphasizes the need for a systemic therapeutic approach to ensure maxi-
mal benefits for all SMA patients throughout their life.
Introduction
Spinal muscular atrophy (SMA) is an autosomal recessive
disorder characterized primarily by motor neuron death.
The incidence of SMA is around 1 in 11,000 live births,
and most patients rapidly succumb to their symptoms.1
More than half of patients with SMA have a severe,
infant-onset form of the disease with a median life expec-
tancy of 12 months without supportive treatment. SMA is
caused by a mutation or deletion in the ubiquitously
expressed Survival motor neuron 1 (SMN1) gene,2 which
produces a protein (SMN) involved in a number of key
cellular pathways, including RNA metabolism and splic-
ing, amongst others (reviewed in 3).
SMA has traditionally been considered a motor neuron
disease. However, this view has evolved as defects in mul-
tiple non-neuronal cell types have been identified.4–18 It is
unclear whether extra-neuronal components contribute to
the clinical picture of SMA (reviewed in 15, 19), but they
may become particularly relevant for SMA patients where
restoration of SMN protein, largely in the nervous system,
has been achieved through therapeutic intervention (e.g.
Nusinersen; 20).
Metabolic defects in SMA have been reported previ-
ously. Pancreatic defects were observed in mouse models
of SMA and in SMA patients.11,12,21 These alterations
appear to be the cause of abnormal glucose
homeostasis.12,21 Furthermore, defects in amino acid
metabolism in SMA have been described.22 Lipid metabo-
lism and fatty acid oxidation defects have also been
reported in early studies of patients with SMA,23,24 where
increased esterified carnitine, and reduced b-oxidation
capacity are seen.24 There are also three reports of
microvesicular steatosis in livers of patients with SMA.24–26
The etiology, importance, or generalizability of these find-
ings remain unclear. Most recently, non-neuromuscular
phenotypes including metabolic defects were reported
prior to their first clinical signs of neuromuscular degen-
eration in SMA patients.27 As such, standard of care state-
ments have highlighted the need for further research in
metabolic status in SMA patients to inform future nutri-
tional guidelines,28,29 but strong comprehensive studies
are currently still lacking.
The primary goal here is to provide foundational evi-
dence of defects in lipid metabolism in SMA patients and
mouse models of SMA. We find an increased propensity
of dyslipidemia in SMA patients as well as hepatic fatty
deposition. Strikingly, the human findings are reproduced
in the Smn2B/- mouse model, which develop nonalcoholic
fatty liver disease (NAFLD) prior to denervation. Alto-
gether, this work highlights the critical need for investiga-
tion of lipid metabolism and the liver in SMA and how
this affects the treatment and care of SMA patients in the
future.
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Methods
Study design
Identification of fatty livers in Smn2B/- mice was serendip-
itous. Upon review of the literature, this sparked a project
with the following objectives: Identify whether findings
are translated in SMA patients and identify the extent of
the fatty acid defect. All objectives were pursued in a
simultaneous manner. The data from SMA patients was
obtained retrospectively in Italy. Pre-clinical data made
use of multiple mouse models of SMA. Serum analysis
and lipid quantification were outsourced, and analyses
were performed in a blinded fashion. Sample size calcula-
tion were not performed for the human data collection as
it was retrospective. N number are described in each fig-
ure legend. Statistical approach is as described below and
in figure captions. Collaboration between laboratories of
Kothary and Parson and colleagues occurred midproject,
given overlapping results that were converging. Hence,
the resulting manuscript offers preclinical data that have
been concordant in two independent laboratories.
Patient data
Infant and young SMA patients were recruited from two
clinical referral centers for SMA in Italy (UO Neurologia
dello Sviluppo, Fondazione IRCCS Instituto Neurologico
Carlo Besta, Milan, Italy and SAPRE-UONPIA, Fon-
dazione IRCCS Ca’ Granda Ospedale Maggiore Policlin-
ico, Milan, Italy). The study protocol was approved by
institution ethics review boards (University of Milan #7/
16 and Carlo Besta Neurological Institute Foundation
#37/2016). All patients with blood work results have
genetically confirmed diagnosis of SMA and they were
explained benefits and risks of the study, and consented
to the study. None of the patients were enrolled in any
clinical trials at the time of the blood draw. This study
used cut-off values proposed by the National Cholesterol
Education Program (NCEP).30 Adult dyslipidemia cut-off
values were extracted from the third report of the
National Cholesterol Education Program (NCEP) expert
panel on Detection, Evaluation and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III)
and The National Lipid Association recommendations for
patient-centered management of dyslipidemia: Part 1 -
executive summary.
Liver pathology of human necropsies
Necropsies were obtained at BC Children’s Hospital (Pro-
tocol #H18-00038). Ten cases of human SMA were
retrieved from the pathology files of the British
Columbia’s Children Hospital and the Children’s Hospital
of Eastern Ontario. Given the timeframe of the necropsies
(between 1977 and 1996), patients were diagnosed based
on clinical presentation and histological features apart
from #6 and #7, which were done after 1992 and were
genetically confirmed. After review, two cases were not
retained: one had associated features of olivo-ponto-cere-
bellar atrophy; the other because of negative familial
genetic studies performed 16 years later and because of
the presence of nonmotor changes at histology, in the
spinal cord. The autopsies were performed between 1977
and 1996. Slides from the liver were available in all cases.
Seven cases were of SMA type I: four females and three
males, aged from less than a month to 3 years. One SMA
type II case was a female aged 13 years.
Mouse models
The Smn-/-;SMN2 (Jackson Laboratory), Smn-/-;SMN2+/+;
SMND7 and Smn2B/- (wild type BL/6J background)31
mouse lines were housed at the University of Ottawa Ani-
mal Facility and cared for according to the Canadian
Council on Animal Care. Experimentation and breeding
were performed under protocol OHRI-1948 and OHRI-
1927. Smn+/- mice were crossed to Smn2B/2B mice to
obtain Smn2B/+ and Smn2B/- animals. C57BL/6J wild-type
mice were bred separately. The Taiwanese Smn-/-;SMN2
(FVB/N background, FVB.Cg-Smn1tm1HungTg(SMN2)
2Hung/J from Jackson Laboratory #005058) and
SOD1G93A mice (B6.Cg-Tg(SOD1*G93A)1Gur/J from
Jackson Laboratory #004435) were housed at the Biomed-
ical Sciences Unit, University of Oxford or within Biologi-
cal Research Resources at the University of Edinburgh.
All experiments using mice in the UK were performed in
accordance with the licensing procedures authorized by
the UK Home Office (Animal Scientific Procedures Act
1986). All tissue for quantitative biochemical analysis
were collected at the same time of the day to limit the
effect of the circadian rhythm.
Tissue handling and histological analysis
Gross morphology, tissue processing, and staining of ani-
mal tissues was as described before.13
Lipid quantification and plasma analysis in
mice
Tissue lipid analysis for quantification and profiles were
performed at the Vanderbilt Mouse Metabolic Phenotyp-
ing Center. Lipids were extracted and analyzed as
described.32,33 Cholesterol and unesterified cholesterol
quantification protocol was adapted from 34. Following
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decapitation of the mice, blood was collected via capillary
using Microcuvette CB 300 K2E coated with K2 EDTA
(16.444.100). All the blood collected in this study was
sampled ad libitum (i.e. no fasting period) between 9 and
11 AM to limit the effect of the circadian rhythm. Samples
were then spun at 2000g for 5 min at room temperature
to extract plasma. Lipoproteins analysis was performed at
the National Mouse Metabolic Phenotyping Center
(MMPC) at the University of Massachusetts Medical
School using a Cobas Clinical Chemistry Analyzer (Roche
Diagnostics, Indianapolis, IN). Blood glucose was
obtained using blood glucose and ketone monitoring sys-
tem FreeStyle Precision Neo and FreeStyle precision glu-
cose strips.
Gene expression studies
RNA from liver and skeletal muscle was extracted using
Qiagen RNeasy Mini kit and reverse transcribed using
RT2 first strand kit according to manufacturer’s protocol.
Qiagen microarray fatty acid metabolism (PAMM-007Z)
and fatty liver (PAMM-157Z) were used and were ana-
lyzed using RT2 Profiler PCR Array Data Analysis
(http://saweb2.sabiosciences.com/pcr/arrayanalysis.php).
Automatic selection from Housekeeping group panel was
used as a method of normalization.
Statistics
Data are presented as the mean  standard error of the
mean. A two-sided Student’s t test was performed using
Microsoft Excel or Graphpad Prism 7 to compare the
means of data when only two groups were compared (i.e.
wild type vs. Smn2B/-). One-way ANOVA analysis was
used to distinguish differences between more than two
groups when multiple comparisons were necessary (i.e.
wild type vs. Smn2B/+ vs. Smn2B/-). The post-test used for
the ANOVA was Tukey. Significance was set at P ≤ 0.05
for *, P ≤ 0.01 for **, P ≤ 0.001 for ***, and P ≤ 0.0001
for ****. N number for each experiment is as indicated
in the figure legends.
Results
SMA patients are at an increased risk of
dyslipidemia and fatty liver
We performed lipid profiling on 72 pediatric SMA
patients (14 type I, 52 type II, 6 type III – demographics
in Table 1). Briefly, the cohort was fairly evenly split
between male (54.17%) and female (45.83%). The median
age for the whole cohort was 3.8 years, while for males
was 3.7 years old and for females was 4 years old. The
median time before their last meal was 5 h. Note that
fasting has minimal effect on lipid levels in comparison
to nonfasting.35 We focused on total cholesterol (TC),
low density lipoprotein (LDL), high density lipoprotein
(HDL), non-HDL, and triglycerides to assess abnormali-
ties in fatty acid metabolism in a minimally invasive man-
ner. Over a third (37.5%) of SMA patients, most
commonly type I and II, had at least one positive readout
out of the five indicative tests for laboratory-defined dys-
lipidemia (Table 2), in comparison to less than a quarter
(20–24%) of the general population in published data
sets.36 Furthermore, close to 20% and 13% of SMA
patients had more than two or three positive readouts
out of the five tests of laboratory-defined dyslipidemia
respectively (Table 2). LDL prevalence was doubled in
comparison to the general pediatric population.36–38
Patients with borderline values made up 61% of SMA
patients with at least one indicative lipid result, and 40%
would have 3 or more (Table 2). Notably, 3/8 (37.5%) of
pediatric SMA liver necropsies revealed steatosis, reminis-
cent of the proportion of SMA patients showing dyslipi-
demia (37.5% as well) (Table 3). This is in marked
contrast to reported prevalence of NALFD in the pediatric
population 2–19 years of age, estimated to be between
2% and 13%.39,40 If we limit the age range to 2–4 years,
which is more in line with our SMA necropsy cohort, it
has been reported that liver steatosis incidence is only
0.7% in the normal pediatric population.40
We next assessed whether any associated glucose mis-
handling defects may be present, as we had previously
identified pancreatic defects.11,12 We obtained HbA1C
data, a measure of the mean glucose level over the previ-
ous 3 months, for 53 of the 72 patients in our cohort.
Interestingly, HbA1C trended lower in most SMA patients,
with 30 of 53 having an abnormally low readout
Table 1. SMA pediatric patient cohort demographics.
Pediatric
cohort Number Percentage
Median age
(years)
Time before last
meal (hours)
Total 72 100 3.8 5
Male 39 54.17 3.7 5
Female 33 45.83 4 5
Type I 14 19.44 3.1 5
Male 5 6.94 2 5
Female 9 12.5 3.2 5
Type II 52 72.22 3.8 5
Male 31 43.05 3.7 5
Female 21 29.17 4.2 5
Type III 6 8.33 6.4 5
Male 3 4.17 6.2 5
Female 3 4.17 6.6 5
1522 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Non-Alcoholic Fatty Liver Disease in SMA M.-O. Deguise et al.
(HbA1C < 5%, normal 5%–6.5%). In fact, most SMA
patients had an HbA1C around 5% as the calculated med-
ian was 4.94% and calculated mean 4.93% in our cohort
(Table 2). Overall, a large subset of SMA patients show
clinical test results consistent with considerable metabolic
abnormalities, especially dyslipidemia and fatty liver.
Abnormal fatty acid metabolism in SMA
mouse models
To investigate whether fatty acid metabolism defects iden-
tified above may be related to SMN depletion, we assessed
livers of the Smn2B/- mouse model at pre-symptomatic
age (postnatal day 4 (P4)) and at symptomatic age (P17–
19). The livers from P17–19 Smn2B/- mice were paler and
displayed microvesicular steatosis (Fig. 1A–B, E–G). The
level of triglycerides, the main storage form of fatty acids,
was 25-fold higher in livers of P19 Smn2B/- mice com-
pared to controls (Fig. 1H). Triglyceride chain length
alterations, especially of long chain fatty acids, were noted
in P19 Smn2B/- mice compared to controls (Fig. 1I–J).
Phospholipid, free fatty acid, diglycerides, cholesterol
esters, unesterified cholesterol and total cholesterol
(Fig. 1K–P) in livers of P19 Smn2B/- mice showed alter-
ations, indicating a global misregulation in fatty acid
metabolism. By comparison, histology (Fig. 1C and D),
Table 2. SMA patients are more susceptible to dyslipidemia than the normal population.
Criteria All SMA patients Type I Type II Type III Normal population*
Abnormal TC > 200 mg/dL 10/72 (13.89%) 1/14 (7.14%) 9/52 (17.31%) 0/6 (0%) 7.7–10.7%36–38
LDL > 130 mg/dL 9/72 (12.5%) 1/14 (7.14%) 7/52 (13.46%) 1/6 (16.67%) 3.2–7.2%36–38
HDL < 40 mg/dL 12/72 (16.67%) 1/14 (7.14%) 10/52 (19.23%) 1/6 (16.67%) 4.1–19.3%36,38,43,57
TG > 100 mg/dL‡ 15/72 (20.83%) 5/14 (35.71%) 7/52 (13.46%) 3/6 (50%) 13.2–22.1%36,38,57
Non HDL-cholesterol > 145 mg/dL 10/72 (13.89%) 1/14 (7.14%) 8/52 (15.38%) 1/6 (16.67%) 8.4%43
1/5 abnormal dyslipidemia reading 27/72 (37.5%) 6/14 (42.85%) 18/52 (34.62%) 3/6 (50%) 20.2–22.9%36,43
2/5 < abnormal dyslipidemia reading 14/72 (19.44%) 2/14 (14.29%) 11/52 (21.15%) 1/6 (16.67%) 5.37%†36
3/5 < abnormal dyslipidemia reading 10/72 (13.89%) 1/14 (7.14%) 8/52 (15.38%) 1/6 (16.67%) –
HbA1C < 5 30/53 (56.60%) 5/8 (62.5%) 23/41 (56.09%) 2/4 (50%)
Borderline TC > 170 mg/dL 30/72 (41.67%) 5/14 (35.71%) 23/52 (44.23%) 2/6 (33.33%) –
LDL > 110 mg/dL 21/72 (29.17%) 2/14 (14.29%) 18/52 (34.62%) 1/6 (16.67%) –
HDL < 45 mg/dL 20/72 (27.78%) 5/14 (35.71%) 13/52 (25%) 2/6 (33.33%) –
TG > 75 mg/dL§ 23/72 (31.94%) 7/14 (50%) 13/52 (25%) 3/6 (50%) –
Non HDL-cholesterol > 120 mg/dL 32/72 (44.44%) 6/14 (42.86%) 23/52 (44.23%) 3/6 (50%) –
1/5 < borderline dyslipidemia reading 44/72 (61.1%) 11/14 (78.57%) 30/52 (57.69%) 3/6 (50%) –
2/5 < borderline dyslipidemia reading 35/72 (48.61%) 6/14 (42.86%) 26/52 (50%) 3/6 (50%) –
3/5 < borderline dyslipidemia reading 29/72 (40.28%) 6/14 (42.86%) 20/52 (38.46%) 3/6 (50%) –
*Note that these values were taken from multiple studies and criteria may have varied and not be identical to the present study.
†Calculated from results in the particular study – see reference.
‡High is defined as >100 for 0–9 years and >130 for 10–19 years of age.
§Borderline is defined as >75 for 0–9 years and >90 for 10–19 years of age.
Table 3. Presence of steatosis in SMA liver necropsies.
Case Sex Age Type Cause death Steatosis*
1 F 14 mo I Bronchopneumonia -/**
2 F 7 mo I Bronchopneumonia -
3 M 8 mo I Aspiration pneumonia +++
4 M <1 mo I Aspiration pneumonia -
5 F 9 mo I Respiratory insufficiency +/++
6 F 14 mo I Bronchopneumonia -
7 M 12 mo I Respiratory insufficiency + HIE + Chronic pneumonitis +/++
8 F 13 y II Undetermined -
HIE, Hypoxic ischemic encephalopathy.
*: -: no steatosis; +: mild panlobular; ++ and +++: moderate and severe, panlobular. In all cases with steatosis (cases 3, 5, and 7), it was of the
microvesicular type, predominantly and the periportal regions were more involved than the mid or central regions of the hepatic lobules.
**: Presence of moderate increase of glycogen.
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and lipid levels (Fig. 1K–P) were unchanged in P4
Smn2B/- livers.
Triglyceride levels were determined in three additional
mouse models of SMA. Fat accumulation was confirmed
in livers from symptomatic P9 SmnD7 mice (Smn-/-;
SMN2+/+;SmnD7+/+) (Fig. 2). Conversely, more severe
mouse models of SMA, such as the “Taiwanese” mice
(P9) and the Smn-/-;SMN2 mice (P5), showed reduced
lipid accumulation in the liver compared to control litter-
mates (Fig. 2A–B), likely due to the reduced life span of
Figure 1. Smn2B/- mice have fat accumulation in the liver. Gross morphology (0.75X) and histology (H&E – 40X, Oil Red O – 400X) of Smn2B/-
livers showing fatty inclusions at P17–19 (A and B, E–G) but not P4 (C and D). Lipid profiling identified elevation of triglycerides at P19 in Smn2B/-
livers (H), with altered chain length (I–J). Other lipid classes, such as phospholipid, free fatty acids, diglycerides, cholesterol esters, unesterified
cholesterol, and total cholesterol, were also misregulated in P19 Smn2B/- livers (K–P). P4 lipid levels were unchanged from control (H, K–P). Scale
bar: (A–D) 50 µm, (E and F) 10 µm. (N value for each experiment is as follows: N = 5–6 for A–D, 3–5 for E–G, 4 for H–P, unpaired two-sided
student’s t-test, *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001).
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these animals preventing the opportunity for these
pathologies to develop (Fig. 2D). A fatty acid pathway-fo-
cused PCR array in liver of symptomatic Smn2B/- and
“Taiwanese” mice, revealed several overlapping alter-
ations, suggesting similar pathogenic etiologies (Fig. 3).
Significantly, lipid metabolism defects are present across
multiple mouse models of SMA. The severity, stage of
disease progression, and genetic background of the mouse
models may influence the extent of lipid accumulation in
the liver and the pathological presentation.
To better understand the mechanisms underlying the
NAFLD in Smn2B/- mice, we next examined the progres-
sion of fat accumulation in the liver. Interestingly, the
liver became progressively fatty starting at P9 (Fig. 4A–E).
This raised the possibility that muscle denervation, which
may start around this time in Smn2B/- mice, could be suf-
ficient to induce liver steatosis. However, SOD1G93A mice,
a well-established model of amyotrophic lateral sclerosis
(ALS) that shows widespread denervation, showed no
hepatosteatosis at symptomatic age (20 weeks) (Fig. 4F–
I). Nevertheless, we cannot discount the possibility that
denervation may yet contribute to a lower metabolic
demand by skeletal muscle or through alterations of
metabolic pathways.
Smn2B/- mice also display dyslipidemia and
abnormal fatty acid metabolism in skeletal
muscle
We next assessed whether Smn2B/- mice displayed dyslipi-
demia and fatty acid metabolism abnormalities in other
tissues. Analysis of plasma lipoproteins from P19 Smn2B/-
mice revealed a significant increase in TC, very low den-
sity lipoprotein (VLDL - derived from triglycerides) and
LDL, while HDL levels were reduced (Fig. 5A–D). Conse-
quently, the ratios of TC/HDL, a measure of increased
cardiovascular risk41 were significantly elevated (Fig. 5E).
In addition, glucose always trended lower and its level
plummeted after P7 in Smn2B/- mice (Fig. 5F). The clear
dyslipidemic profile and low glucose levels align well with
our clinical findings in SMA patients. We then deter-
mined if the altered lipoprotein in the plasma translated
to an increased delivery of lipids to motor neurons and
skeletal muscle, two primary targets in SMA pathogenesis.
No changes were observed in the spinal cord and tibialis
anterior muscle of P19 Smn2B/- mice (Fig. 5G and H).
Given that we had previously identified fatty infiltrates in
the skeletal muscle of Smn2B/- mice,42 we further investi-
gated whether some alterations in lipid metabolism path-
ways are present despite no change in triglyceride
content. A focused fatty acid PCR array showed that a
number of genes were misregulated in muscles of these
mice (Fig. 5I). These data suggest that fatty acid metabo-
lism is dysregulated in different tissues in SMA mice.
Discussion
Studies from three decades ago had identified potential
fatty acid defects with dicarboxylic aciduria, and reduced
muscle fatty oxidation, with three subsequent reports of
hepatic fatty vacuolization in SMA patients.23–26 Despite
these initial findings and the recognition for studies in
Figure 2. Hepatic triglyceride misregulation is a common feature in different SMA models at symptomatic. Quantification of hepatic triglycerides
showed a fivefold reduction in P5 Smn-/-; SMN2 mice (A), a twofold reduction in P9 Taiwanese mice (B), and a threefold increase in P10 SmnD7
mice (C) in comparison to control littermates. Analysis of hepatic triglyceride levels for each SMA mouse model in A–C involved a comparison to
their own control (N value for each experiment is as follows: N = 4–6 for A and B, 9–10 for C, 4–9 for D, unpaired two-sided student’s t-test,
*P ≤ 0.05 and **P ≤ 0.01).
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Figure 3. Commonalities identified in expression of fatty acid metabolism genes between Taiwanese and Smn2B/- mice. Volcano plot presentation
of all changes (1.5X, P < 0.05) in a focused fatty acid metabolism PCR array in Smn2B/- mice (A) and Taiwanese mice (C) identify general
downregulation. Changes more than two-fold are represented for Smn2B/- (B) and Taiwanese (D). Analysis of commonalities between Smn2B/- and
Taiwanese are represented by Venn diagrams, which identify nine genes with similar changes (E), listed in (F). (N = 4, for Smn2B/- mice, and N = 3
for Taiwanese mice).
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metabolic defects in SMA by consensus statements in the
care of SMA patients,28,29 minimal research has been
done to fill this gap. Indeed, systematic research on fatty
acid metabolism in SMA has remained largely unexplored
and translational foundational data are lacking. We show
that patients with SMA are more prone to develop dys-
lipidemia as well as liver steatosis than the general pedi-
atric population,36–38,40,43 with a large subset showing
abnormalities when screened with a common lipid and
cholesterol panel and in SMA liver necropsies. In preclini-
cal models, fatty acid abnormalities were identified in
four commonly used SMA mouse models. With a focus
on the Smn2B/- mice, we observe the development of a
NAFLD phenotype that does not appear to be caused by
the denervation.
In this study, we provide strong evidence for the sus-
ceptibility to dyslipidemia and low glycated hemoglobin
levels in a large cohort of SMA patients. To our knowl-
edge, this is the first time that such abnormalities are
reported in SMA. Current statistics on dyslipidemia in
one laboratory-defined measure in otherwise healthy chil-
dren is estimated to be roughly 20%.36,43 Our studies
showed that 37% of SMA patients have dyslipidemia.
More strikingly, 14% of patients had more than 3 labora-
tory-defined measures of dyslipidemia, for which preva-
lence data is sparse in the normal pediatric population
but is suspected to be quite low in the absence of familial
dyslipidemia. Pathological examination of SMA liver
necropsies showed a similar proportion (37.5%) display-
ing liver steatosis. This is much higher than the preva-
lence of liver steatosis in 2–4 year old normal children
(0.7%).40 The proportion of fatty liver in our SMA sam-
ples was closer to fatty liver prevalence reported in older
obese pediatric population, where prevalence can range
from 28–77%.39 Additionally, low HbA1C, observed in the
majority of our cohort, has been associated with increased
all-cause mortality44 and liver disease45 in the general
population. Given the significant size of our cohort, we
suggest that dyslipidemia is an important feature of SMA.
Early metabolic studies on SMA patients had focused on
urinary organic acids, muscle b-oxidation enzyme func-
tion, and plasma acylcarnitine and free fatty acid profil-
ing.23,24,26 These tests are rarely used, are not widely
available, and their interpretation requires a specialist’s
advice, hence making them poor choices in the screening
and identification of SMA patients with potential meta-
bolic abnormalities. Our study provides a widely accessi-
ble manner to identify and monitor fatty acid metabolic
abnormalities in SMA patients that can be acted upon
with current cholesterol-lowering therapy if needed.
While necropsies were used for the identification of fatty
liver in this study, this can be easily determined through
ultrasonography, which consists of a widely used and
non-invasive imaging modality.46 In the upcoming years,
screening and preventive treatment of dyslipidemia and
fatty liver could be particularly important to limit signifi-
cant co-morbidities, such as cardiovascular and cere-
brovascular disease, in the newly aging demographics of
treated SMA patients.
While dyslipidemia and liver steatosis were present in
a subset of SMA patients, these phenotypes were present
in all Smn2B/- mice studied. This is perhaps not surprising
as the human population is much more heterogenous
than congenic mouse colonies. Nevertheless, the consis-
tency of these findings in human and a preclinical model
make it clear that SMN depletion predisposes the organ-
ism to fatty acid defects, dyslipidemia, and NAFLD. It is
likely that other gene polymorphisms may be required
for (or even protect against) the onset and severity of
these phenotypes. Similarly, investigation of hepatic fatty
accumulation in four different mouse models of SMA all
revealed abnormalities, following an interesting pattern of
presentation. It appears that the severity of disease model
and related period of survival critically modulates how
the alterations in fatty acid metabolism present, reminis-
cent of our findings in skeletal muscle.5,42 We identified
that the most severe mouse models (Smn-/-;SMN2, and
“Taiwanese” mice) show low lipid content in the liver
while less severe and slightly longer lived SMA models
(Smn-/-;SMN2+/+;SmnD7+/+ and Smn2B/- mice) display
liver steatosis. Even though liver pathology presentation
in the “Taiwanese” and Smn2B/- mice differs, we identi-
fied nine genes in a fatty liver PCR array with similar
patterns of misregulation. Their expression profile as a
whole were in line with a compensatory mechanism to
limit further triglyceride accumulation. This suggests that
some of the molecular etiologies are likely the same, but
sufficient time (i.e. longer survival) and perhaps some
genetic modifiers may be required to develop the fat
accumulation.
A common question in non-neuronal findings in SMA
is whether it is a consequence of denervation. In other
diseases where denervation is present, such as in spinal
cord injury (SCI)47 and spinal and bulbar muscular atro-
phy (SBMA),48 some reports identify an increased risk for
dyslipidemia. However, SCI and SBMA patients are gen-
erally older adults and dyslipidemia is well-known to be
more prominent with age. Thus, generalizing these results
to the SMA population is not obvious. In addition, these
reports47,48 do not account for prevalence of patients with
multiple measures of dyslipidemia, such as in our study.
A major limitation of our study was the absence of a den-
ervated patient control group. However, previous studies
had shown that fatty acid alterations in SMA patients
could not be explained by denervation alone, as dener-
vated control patients did not display these defects.23
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Nevertheless, to overcome this limitation, we turned to
preclinical mouse models. We found that denervation,
such as in the SOD1G93A mouse model of ALS, did not
lead to development of liver steatosis. Previous literature
in ALS described lipid redistribution rather than accumu-
lation in SOD1G93A mice, consistent with our findings.49
It should be noted that this model is also associated with
increased lipid clearance in the periphery, which could
abrogate fatty accumulation brought on by denervation.50
Interestingly, we found that the rate of triglyceride accu-
mulation in the liver increases very rapidly with progres-
sion of disease in the mouse, which could reflect the
overall denervation status of the animal. Indeed, it is pos-
sible that denervation plays some role in induction of this
phenotype by changing the metabolic demand of the
muscle, modulating the molecular metabolism upon den-
ervation, or through other unknown factors.
In simple terms, we believe that NAFLD develops
through the imbalance of input (diet, peripheral lipolysis,
de novo lipogenesis) and output (export of lipids or
usage through b-oxidation). We propose that this pheno-
type in SMA could be caused by potential perturbation in
the pancreas-liver axis (as exemplified by the low blood
glucose), potential mitochondrial defects, liver-intrinsic
defects, or the interplay of the three. Indeed, it appears
that hyperglucagonemia, a characteristic found in Smn2B/-
mice12 likely in response to low blood sugar, can lead to
peripheral lipolysis of white adipose tissue and increase in
circulating lipids.51 Mitochondrial defects have previously
been identified in other cell types as well as in human
muscle biopsies52–54 and could likely contribute to reduce
b-oxidation in hepatocytes. Additionally, the unknown
splicing deficiency in the hepatocytes could predispose
the cells to fat accumulation. Another possibility, in the
context of low glucose, includes severe starvation, which
also been linked to NAFLD development.55 Nevertheless,
the NAFLD phenotype observed in Smn2B/- mice occurs
prior to overt motor dysfunction that would thus not
prevent the mice from obtaining appropriate nutrition.
Moreover, in the case of SMA patients, they are generally
followed by nutritionists to ensure appropriate caloric
intake. Further molecular studies should attempt to dis-
sect the etiologies and identify nutritional or therapeutic
strategies to abrogate this co-morbidity in susceptible
patients.
The extent of fatty accumulation identified in Smn2B/-
mice is likely to result in functional consequences. The
liver is the metabolic factory of the body, producing plas-
matic proteins, processing toxins as well as medications,
and regulating glucose, lipid, and amino acid homeostasis.
Going forward, the functionality of the liver in SMA will
be a particularly important consideration in formulation
of new therapeutic for SMA. Indeed, pro-drugs metabo-
lized through the liver may not gain optimal levels while
those cleared/processed by the liver might harbor more
significant hepatotoxicity. In fact, historically there has
been only cursory examination of liver function in SMA.
Embryonic lethality and iron overload are the main fea-
tures of liver restricted Smn conditional knockout in
mice.56 More recently, increased erythropoiesis, megakary-
ocyte and platelet production, together with mild iron
storage abnormalities, were identified in the severe
“Taiwanese” mouse model of SMA.10
Altogether, our clinical studies in SMA patients as well
as in preclinical mouse models, provide strong evidence
of defects in fatty acid metabolism. The greater predispo-
sition to develop dyslipidemia and fatty liver in SMA
patients as well as the identification of NAFLD in Smn2B/-
mice emphasize that defects in metabolism can lead to
added co-morbidities, especially in the new therapeutic
era of SMA, where lifespan is extended. Indeed, this work
further highlights the importance of establishing currently
lacking nutritional guidelines, performing early screening
for metabolic defects in treated SMA patients, as well as
developing systemic therapeutic strategies that incorporate
non-neuronal organs to ensure overall optimal manage-
ment of SMA.
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